广东省药品监督管理局关于化妆品监督检查的通告（2025年第3期）

Core Viewpoint - The Guangdong Provincial Drug Administration conducted inspections on 106 cosmetic manufacturing companies, revealing that 33 of them had serious deficiencies in their production quality management systems, leading to immediate regulatory actions to suspend production and operations to mitigate product risks [3][4]. Group 1: Regulatory Actions - The Guangdong Provincial Drug Administration has mandated local drug supervision departments to take urgent control measures against the identified companies, including orders to suspend production and operations [3]. - The inspections were based on regulations such as the "Cosmetic Supervision and Administration Regulations" and "Cosmetic Production Quality Management Standards" [3]. Group 2: Companies Affected - A total of 33 companies were found to have serious deficiencies in their production quality management systems, and a list of these companies has been provided [3][4]. - The list includes companies such as Guangdong Qiaoneng Biotechnology Co., Ltd., Guangzhou Meike Pharmaceutical Biotechnology Co., Ltd., and Guangzhou Yiqifina Biotechnology Co., Ltd., among others [3][4].